At the World Congress of Nephrology 2026 in Yokohama, Japan, growing attention is being paid not just to whether therapies improve outcomes in chronic kidney disease, but how they work at a mechanistic level.

In this episode of Kidney Compass, host Brendon Neuen, MBBS, PhD, spoke with David Cherney, MD, PhD, about the REMODEL trial, a mechanistic study designed to better understand the kidney-protective effects of semaglutide in patients with type 2 diabetes and chronic kidney disease.

0:00:00 – Episode intro & guest setup
0:00:54 – What is REMODEL & link to FLOW
0:01:21 – Design, outcomes & mechanistic readouts of REMODEL
0:04:30 – Additive effects with SGLT2 inhibitors
0:07:17 – Perirenal fat, venous pressure & “toxic adiposity”
0:10:28 – Relevance to non‑diabetic CKD & SMART trial link
0:13:20 – Clinical messaging & patient communication

https://www.hcplive.com/view/kidney-compass-remodel-trial-provides-mechanistic-rationale-for-semaglutide-in-ckd